

January NEWSLETTER

MROQC February Collaborative-Wide Webinar

We are just a few weeks away from the MROQC February Collaborative-Wide **VIRTUAL** webinar!

Friday, February 23rd, 2024 9:00am-12:00pm

Our MROQC Coordinating Center has put together an excellent agenda, which will be shared one week before the meeting. Don't forget to register as soon as possible. Click **HERE** to register and secure your zoom link!

Breakout Sessions/Registration

Physics|Dosimetry Breakout Monday, February 12, 2024 10:00a-11:00a **Registration**

<u>CDA Breakout</u> Tuesday, February 13, 2024 10:00a-11:00a **Registration**

<u>Clinical Champions, Participating Physicians,</u> <u>and Site Administrators Breakout Session</u> (meeting will take place after the main meeting) Friday, February 23rd, 2024 1:00p-2:00p <u>Registration</u>

In this Issue:

February Collaborative Wide Meeting

2023 P4P Scorecards

February Monthly Reports

BCBSM Biannual Survey

2024 FTE Model

MROQC AI Contouring Survey

Behavioral Oversight Naming Contest

Upcoming Meetings and Events

2024 Collaborative-Wide Meetings

2023 Pay For Performance Scorecards and Case Volumes

The 2023 Quality Initiative Performance Index Measures (P4P) score with the 2023 case volume highlighting your facility's participation in the BCBSM Michigan Radiation Oncology Quality Consortium (MROQC) will be issued on February 1st.

If you have any questions about the calculated score or reported volume, inquiries must

be sent to **support@mroqc.org** by **12 p.m. on Monday, February 19th.** We ask that you do not send direct emails to any of the coordinating center staff to help us expedite responses to your questions.

MROQC will be reporting the final overall score and case volume to the P4P administrators at your facility and to BCBSM on March 1st, 2024.

ogy Quality Consortium	QUALITY INITIATIVE PERFORMANCE INDEX MEASURES (P4P) 2023	
Weight	Measure Description	Points earned
#1 10	High Quality Clinical and Physics Data Submission and Completeness ¹	currice
		10
		8
		4
	One Data Quality Metric Met	2
	None of the Data Quality Metrics Met	0
#2 5	Submission of Technical Data (Full DICOM-RT data and Physics Radiotherapy	
	Technical Details Survey) for Breast, Lung, and Complex Bone Mets Cases	
	>85% of technical data submitted within six weeks of treatment completion	5
	>85% of technical data submitted within eight weeks	4
	>85% of technical data submitted within twelve weeks	3
	>85% of technical data submitted after twelve weeks	2
	<85% of technical data submitted after twelve weeks	0
#3 10	In node-positive breast cancer patients for whom the supraclavicular(SCV)	
	is(are) contoured and named per TG-263 naming convention AND the dose is	
	reported.	
	Contours and dose reported in ≥60% of patients	10
	Contours and dose reported in 40-59% of patients	7
	Contours and dose reported in <40% of patients	0
#4 10	Mean heart dose achieved in breast patients receiving conventionally	
	fractionated radiotherapy to supraclavicular, infraclavicular, and/or internal	
	mammary nodes ²	
	≥85% of patients meet heart sparing goals	10
	60-84% of patients meet heart sparing goals	7
	<60% of patients meet heart sparing goals	0
#5 10	Collection rate of annual lung follow-up for those due for 1 st year follow-up	
		10
	60-74% rate of annual lung follow-up	7
	<60% rate of annual lung follow-up	0
#6 10	For lung cancer patients: evaluate Task Group-263 compliance for the specified	
	≥80% compliance for the specified structures	10
	60-79% compliance for the specified structures	7
	<60% compliance for the specified structures	0
#7 1 0		
	A: The MROQC consortium-wide rate of single fraction use is ≥45% for uncomplicated patients ³	
	B: Your site-level rate of ≤5 fraction treatment is at least 60% for all patients	
	A and B are met	10
		7 0
	10 5 10 10 10 10	Weight Measure Description 10 High Quality Clinical and Physics Data Submission and Completeness' Four Data Quality Metrics Met Three Data Quality Metrics Met 11 Two Data Quality Metrics Met Two Data Quality Metrics Met 12 Submission of Technical Data (<i>Full DICOM-RT data and Physics Radiotherapy</i> Technical Details Survey) for Breast, Lung, and Complex Bone Mets Cases >85% of technical data submitted within six weeks of treatment completion >85% of technical data submitted within eight weeks >85% of technical data submitted after twelve weeks <85% of technical data submitted after twelve weeks <85% of technical data submitted after twelve weeks

BCBSM Biennial Survey

In an effort to evaluate the effectiveness of the Collaborative Quality Initiative Coordinating Centers, Blue Cross Blue Shield of Michigan and Blue Care Network, once again, requests your participation in filling out the Biennial CQI Coordinating Center evaluation survey for MROQC.

The survey is open until February 7th, 2024.

Anonymous responses will go directly to BCBSM.

By clicking on the specific hyperlinks below, you



will be routed directly to the specific survey that you are requested to complete. Please click on the appropriate link below according to your role in MROQC shown below:

- 1. Michigan Radiation Oncology Quality Consortium (MROQC) Radiation Oncologists Survey
- 2. Michigan Radiation Oncology Quality Consortium (MROQC) Physicists/Dosimetrists/CDAs Survey

Should you have any questions or concerns, please feel free to contact**BCBSM CQI** Administration via email at CQIPrograms@bcbsm.com

Thank you for taking the time and effort to provide feedback regarding MROQC through this survey.

Renaming Contest for our Behavioral Oversight Committee!



Exciting news! Our Behavioral Oversight Committee is evolving to better align with our mission of identifying and addressing health disparities experienced by our patients. To celebrate this transformative journey, we're thrilled to announce a renaming contest, and we want your creative input!

This is your chance to be a part of shaping the future of our committee and reflecting its commitment to fostering health equity in all aspects of our work. We believe a new name will not only capture the essence of our mission but also inspire unity and collaboration.

How to participate: Submit your creative name suggestions for the committee to support@mroqc.org by February 9, 2024.

The Coordinating Center will select the top 3 choices and send them to MROQC members for voting.

The winner will be announced during February's Collaborative Wide Meeting.

What's in it for you? The winning entry will receive an **MROQC Yeti Mug**, along with the pride of leaving a lasting impact on our health equity initiatives.

Recruitment for committee members will begin in February

FTE (Full Time Equivalent) Model



The 2024 MROQC FTE Model has been approved by BCBSM. The average Number of Cases per 1.0 Full Time Equivalent (FTE) for 2024 will be **187** cases, down from 200.

FTE=number of cases at a given site/187

A single FTE should be expected to effectively manage 187 eligible cases, and the site should staff the MROQC project accordingly with a Clinical Data Abstractor (CDA) to coordinate capture of clinical data and patient reported outcomes, AND a physicist or dosimetrist to report technical details of treatment planning and delivery.

Questions regarding the FTE model can be sent to MROQC Program Manager, Melissa Mietzel.

Resources

MiM AI Auto-Contouring Webinar

1/31/24 3 p.m. ET

Al auto-contouring sounds great in concept, but how does it fit into your clinic? Does it actually improve your contouring process?

This webinar will introduce you to **Contour ProtégéAl+**, the newest zeroclick AI auto-contouring solution from MIM Software.

Unlike other auto-contouring tools, Contour ProtégéAl+ requires no clicks. Contouring of lymph node level and OAR structures starts automatically, and no manual intervention is required to launch. Results are exported directly to the TPS or MIM for review.

Register here: https://go.mimsoftware.com/events/202 4/webinar/cpai-plus

MROQC AI Contouring Survey

To highlight the voices of our MROQC patients captured via our Patient Reported Outcomes forms, the Prostate Working Group has put together a new report, the MROQC Prostate Biannual Report.

This report incorporates:

- Enrollment Summary Data
- Baseline/Follow-Up Form Completion Rates
- Site-Level Patient Reported Outcomes from enrolled Prostate patients.

Upcoming Meetings and Events

MROQC Working Groups



Monday, March 18th, 12:00 p.m.



Tuesday, March 26th, 12:00 p.m.



Wednesday, March 20th, 12:00p.m.



Thursday, March 28th @ 12:00p.m.

Please visit **Quality Working Groups** on the MROQC website for more information about our projects and working group call schedules.

Interested in joining one of our working groups? Click here.

CDA Office Hours

2nd Tuesday of the month 10:00 – 11:30 a.m.

*Look for emails every month to sign up.

2024 Collaborative-Wide Meetings

February 23, 2024 9:00 a.m.-12:00 p.m. VIRTUAL

May 17, 2024 10:00 a.m. to 3:00 p.m. Baronette Renaissance Hotel, Novi

> October 11, 2024 10:00 a.m. to 3:00 p.m. Radisson Plaza, Kalamazoo

For more information, including past events and CE information, please visit the **Consortium Meeting & Events** page on our website.



MROQC | Arbor Lakes, 4251 Plymouth Road, Building 2 Floor 3, Ann Arbor, MI 48105

Unsubscribe mroqccoordinatingcenter@med.umich.edu

Update Profile |Constant Contact Data Notice

Sent bymroqccoordinatingcenter@med.umich.edupowered by



Try email marketing for free today!